BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 32989019)

  • 21. Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.
    Schreuders EH; Grobbee EJ; Nieuwenburg SAV; Kapidzic A; van Roon AHC; van Vuuren AJ; Lansdorp-Vogelaar I; Spijker WWJ; Izelaar K; Bruno MJ; Kuipers EJ; Spaander MCW
    Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):622-631. PubMed ID: 31196734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fecal immunochemical test in colorectal cancer screening: Colonoscopy findings by different cut-off levels.
    Ribbing Wilén H; Blom J; Höijer J; Hultcrantz R
    J Gastroenterol Hepatol; 2019 Jan; 34(1):103-112. PubMed ID: 29968937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fecal immunochemical test in cancer screening - colonoscopy outcome in FIT positives and negatives.
    Ribbing Wilén H; Blom J; Höijer J; Andersson G; Löwbeer C; Hultcrantz R
    Scand J Gastroenterol; 2019 Mar; 54(3):303-310. PubMed ID: 30907196
    [No Abstract]   [Full Text] [Related]  

  • 24. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
    Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
    BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of time between faecal immunochemical tests in colorectal cancer screening on screening results: A natural experiment.
    Ribe SG; Botteri E; Løberg M; Randel KR; Kalager M; Nilsen JA; Gulichsen EH; Holme Ø
    Int J Cancer; 2023 Apr; 152(7):1414-1424. PubMed ID: 36346118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lower Abnormal Fecal Immunochemical Test Cut-Off Values Improve Detection of Colorectal Cancer in System-Level Screens.
    Berry E; Miller S; Koch M; Balasubramanian B; Argenbright K; Gupta S
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):647-653. PubMed ID: 31085338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double-contrast barium enema is no longer justified as a backup examination for colonoscopy in the population screening program: Population study in an organized fecal immunochemical test-based screening program.
    Hsu WF; Su CW; Hsu CY; Yen AM; Chen SL; Chiu SY; Lee YC; Hsu TH; Lin LJ; Chia SL; Wu MS; Chen HH; Chiu HM;
    J Gastroenterol Hepatol; 2023 Aug; 38(8):1299-1306. PubMed ID: 37078599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colonoscopy Versus Fecal Immunochemical Test for Reducing Colorectal Cancer Risk: A Population-Based Case-Control Study.
    Kim SY; Kim HS; Kim YT; Lee JK; Park HJ; Kim HM; Kang DR
    Clin Transl Gastroenterol; 2021 Apr; 12(5):e00350. PubMed ID: 33928919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT-based CRC screening program.
    Breekveldt ECH; Toes-Zoutendijk E; van de Schootbrugge-Vandermeer HJ; de Jonge L; Kooyker AI; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    Int J Cancer; 2023 Apr; 152(8):1536-1546. PubMed ID: 36444504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colonoscopy vs. Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM): Rationale for Study Design.
    Dominitz JA; Robertson DJ; Ahnen DJ; Allison JE; Antonelli M; Boardman KD; Ciarleglio M; Del Curto BJ; Huang GD; Imperiale TF; Larson MF; Lieberman D; O'Connor T; O'Leary TJ; Peduzzi P; Provenzale D; Shaukat A; Sultan S; Voorhees A; Wallace R; Guarino PD
    Am J Gastroenterol; 2017 Nov; 112(11):1736-1746. PubMed ID: 29016565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic accuracy of faecal immunochemical test for screening individuals with a family history of colorectal cancer.
    Ng SC; Ching JY; Chan V; Wong MC; Suen BY; Hirai HW; Lam TY; Lau JY; Ng SS; Wu JC; Chan FK; Sung JJ
    Aliment Pharmacol Ther; 2013 Oct; 38(7):835-41. PubMed ID: 23957462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.
    Wieten E; Schreuders EH; Nieuwenburg SA; Hansen BE; Lansdorp-Vogelaar I; Kuipers EJ; Bruno MJ; Spaander MC
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1771-1777. PubMed ID: 27567693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme.
    Kallenberg FG; Vleugels JL; de Wijkerslooth TR; Stegeman I; Stoop EM; van Leerdam ME; Kuipers EJ; Bossuyt PM; Dekker E
    Aliment Pharmacol Ther; 2016 Jul; 44(1):88-96. PubMed ID: 27170502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Faecal haemoglobin concentrations are associated with all-cause mortality and cause of death in colorectal cancer screening.
    Kaalby L; Deding U; Al-Najami I; Berg-Beckhoff G; Bjørsum-Meyer T; Laurberg T; Shaukat A; Steele RJC; Koulaouzidis A; Rasmussen M; Kobaek-Larsen M; Baatrup G
    BMC Med; 2023 Jan; 21(1):29. PubMed ID: 36691009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One-sample quantitative and two-sample qualitative faecal immunochemical tests for colorectal cancer screening: a cross-sectional study in China.
    Wang L; Chen H; Zhu Y; Lu M; Wang Y; Chen X; Ma W; Du L; Chen W
    BMJ Open; 2022 May; 12(5):e059754. PubMed ID: 35589365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
    Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
    Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interval cancers in a national colorectal screening programme based on faecal immunochemical testing: Implications for faecal haemoglobin concentration threshold and sex inequality.
    Clark GR; Godfrey T; Purdie C; Strachan J; Carey FA; Fraser CG; Steele RJ
    J Med Screen; 2024 Mar; 31(1):21-27. PubMed ID: 37469171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Faecal immunochemical test-based colorectal cancer screening in Mexico: an initial experience.
    Remes-Troche JM; Hinojosa-Garza G; Espinosa-Tamez P; Meixueiro-Daza A; Grube-Pagola P; Van Loon K; Potter MB; Lajous M
    Fam Pract; 2020 Jul; 37(3):321-324. PubMed ID: 31961429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic accuracy of a quantitative faecal immunochemical test vs. symptoms suspected for colorectal cancer in patients referred for colonoscopy.
    Tsapournas G; Hellström PM; Cao Y; Olsson LI
    Scand J Gastroenterol; 2020 Feb; 55(2):184-192. PubMed ID: 31906738
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.